▲ 43 r/ACHR
Archer patents motorcycle design...
Very interesting...
US Patent number: D1140781
u/Lunar_Excursion — 9 days ago
▲ 47 r/ACHR
Archer's pivot into an aerospace defense company is now complete...
MISSILES???
u/Lunar_Excursion — 9 days ago
▲ 13 r/FoundayoPill
Foundayo approved in the UK for obesity and type 2 diabetes
The UK is the fifth country to approve Foundayo for obesity and the second to approve Foundayo for type 2 diabetes.
u/Lunar_Excursion — 10 days ago
▲ 8 r/FoundayoPill
Orforglipron Approved in Mexcio for Obesity and Type 2 Diabetes
The brand name will be called Foundayz
u/Lunar_Excursion — 16 days ago
▲ 5 r/FoundayoPill
Saudi Arabia approves Foundayo
This is the fourth country to approve Foundayo after USA, UAE and Mexico.
u/Lunar_Excursion — 17 days ago
▲ 38 r/ACHR
Halo is intended to “fly further, at higher speed, carrying substantially more weight” than Midnight
u/Lunar_Excursion — 28 days ago
▲ 31 r/ACHR
"Similar payload to the Apache"
another tidbit: "comparable in size to Midnight"
https://theaircurrent.com/defense/the-engineering-behind-anduril-archer-thunder-drone-evtol/
u/Lunar_Excursion — 1 month ago
When controlled for gender and ethnicity, Foundayo shown to be as effective as Wegovy pill
new data from the ENDO 2026 conference shows what we knew all along, that the when you control for the high population of women and whites in the OASIS-4 trial, Foundayo is as effective as Wegovy pill...
as a refresher, OASIS-4 trial was a 307 patient trial with not very diverse demographics: 79% female and 92% white. ATTAIN-1 was a 3127 patient trial with 64% female and 57% white.
u/Lunar_Excursion — 2 months ago
It turns out that Wegovy Pill's "higher efficacy" was actually just a lot of super responders in the trial
In fact more than 70% of patients in the OASIS-4 trial only lost an average of 11.5% of their body weight... most people who take Wegovy Pill will not see the advertised average weight loss because the average was pulled up by these super responders...
and funny enough, the listed weight loss of the non-super responders is inline with what we see in the Foundayo trial, which was much larger and had a much more diverse patient population.
so the narrative that Wegovy is magically more effective while agonizing the same receptors has just been inadvertently killed by Novo's own data...
u/Lunar_Excursion — 3 months ago
Let's see what kind of coverage they will have...
since Lilly has applied for T2D indication on the CNPV, i think approval is in the bag and perhaps these PBM deals were signed with that in mind
base case: it replaces Rybelsus/Ozempic pill on the formulary simply due to cost
best case: it gets coverage like Januvia/Tradjenta and Farxiga/Jardiance because it lowers A1c much more, better MACE benefits, and costs about the same...
the DPP-4's and SGLT2's are all going generic soon so it makes sense to "give that spot" to Foundayo based on the profoundly better health outcomes for essentially the same price.
u/Lunar_Excursion — 4 months ago